パーキンソン病に対する水素水摂取の有効性：無作為化二重盲検プラセボ対照パイロット試験
Oxidative stress is implicated in Parkinson's disease (PD) progression, and molecular hydrogen has demonstrated antioxidant properties in preclinical models. This randomized, double-blind, placebo-controlled pilot study enrolled 17 Japanese PD patients receiving levodopa, who consumed either 1,000 mL/day of hydrogen-rich water or placebo water over 48 weeks. The primary endpoint was change in total Unified Parkinson's Disease Rating Scale (UPDRS) score. The hydrogen-rich water group (n=9) showed a median UPDRS improvement of −1.0 (mean −5.7 ± 8.4), while the placebo group (n=8) showed a median worsening of 4.5 (mean 4.1 ± 9.2). The between-group difference reached statistical significance (P<0.05) despite the small sample size and limited duration. No safety concerns were identified.
Molecular hydrogen is proposed to selectively neutralize reactive oxygen species, particularly hydroxyl radicals, thereby reducing the oxidative stress implicated in Parkinson's disease pathology.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/23400965